1
|
Guo C, Zhang G, Wu C, Lei Y, Wang Y, Yang J. Emerging trends in small molecule inhibitors targeting aldosterone synthase: A new paradigm in cardiovascular disease treatment. Eur J Med Chem 2024; 274:116521. [PMID: 38820853 DOI: 10.1016/j.ejmech.2024.116521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Revised: 05/01/2024] [Accepted: 05/19/2024] [Indexed: 06/02/2024]
Abstract
Aldosterone synthase (CYP11B2) is the rate-limiting enzyme in aldosterone production. In recent years, CYP11B2 has become an appealing target for treating conditions associated with excess aldosterone, such as hypertension, heart failure, and cardiometabolic diseases. Several small-molecule inhibitors of CYP11B2 have demonstrated efficacy in both preclinical studies and clinical trials. Among them, the tetrahydroisoquinoline derivative Baxdrostat has entered clinical trial phases and demonstrated efficacy in treating patients with hypertension. However, the high homology (>93 %) between CYP11B2 and steroid-11β-hydroxylase (CYP11B1), which catalyzes cortisol production, implies that insufficient drug specificity can lead to severe side effects. Developing selective inhibitors for CYP11B2 remains a considerable challenge that requires ongoing attention. This review summarizes recent research progress on small-molecule inhibitors targeting CYP11B2, focusing on structure-activity relationships (SAR) and structural optimization. It discusses strategies for enhancing the specificity and inhibitory activity of inhibitors, while also exploring potential applications and future prospects for CYP11B2 inhibitors, providing a theoretical foundation for developing the new generation of CYP11B2-targeted medications.
Collapse
Affiliation(s)
- Cuiyu Guo
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, Sichuan, China; Department of Pulmonary and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China
| | - Guangbing Zhang
- Frontier Innovation Center for Dental Medicine Plus, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, Sichuan, China
| | - Chengyong Wu
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, Sichuan, China; Department of Pulmonary and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China
| | - Yi Lei
- General Practice Ward/International Medical Center Ward, General Practice Medical Center, General Practice Research Institute, West China Hospital, Sichuan University, China.
| | - Yuxi Wang
- Department of Pulmonary and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, Precision Medicine Key Laboratory of Sichuan Province & Precision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
| | - Jinliang Yang
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, Sichuan, China; Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Chengdu, 610041, Sichuan, China.
| |
Collapse
|
2
|
Meguro M, Miyauchi S, Kanao-Arisumi Y, Naito S, Suzuki K, Inoue S, Yamada K, Homma T, Chiba K, Nara F, Furuzono S. Identification of sulfonylpyrimidines as novel selective aldosterone synthase (CYP11B2) inhibitors. Bioorg Med Chem 2024; 108:117775. [PMID: 38851000 DOI: 10.1016/j.bmc.2024.117775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2024] [Revised: 05/22/2024] [Accepted: 05/25/2024] [Indexed: 06/10/2024]
Abstract
4-[(5-[2-Methyl-5-(methylsulfonyl)pentan-2-yl]sulfonylpyrimidin-4-yl)amino]benzonitrile 2 was identified as a novel potent aldosterone synthase inhibitor. Compound 2 was found to inhibit human CYP11B2 in the nanomolar range, and showed an aldosterone-lowering effect in a furosemide-treated cynomolgus monkey model. Although human CYP11B2 has the high homology sequence with human CYP11B1, compound 2 showed more than 80 times higher selectivity over human CYP11B1 in vitro.
Collapse
Affiliation(s)
- Masaki Meguro
- Shinagawa R&D Center, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.
| | - Satoru Miyauchi
- Technology Division, Technology Business Management Group, Daiichi Sankyo Co., Ltd., 1-12-1, Shinomiya, Hiratsuka-shi, Kanagawa 254-0014, Japan
| | - Yukiko Kanao-Arisumi
- Pharmaunion Co., Ltd., 1-23-39 Hiikawa, Jounan-ku, Fukuoka-shi, Fukuoka 814-0153, Japan
| | - Satoru Naito
- Site Operations Department, Shinagawa Site Operation Group, Daiichi Sankyo Business Associe Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Kanae Suzuki
- Shinagawa R&D Center, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Shinichi Inoue
- Daiichi Sankyo Inc., 211 Mt. Airy Road, Basking Ridge, NJ 07920, USA
| | - Keisuke Yamada
- Medical Affairs Division, Medical Affairs Planning Department, Daiichi Sankyo Co., Ltd., 3-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8426, Japan
| | - Tsuyoshi Homma
- Shinagawa R&D Center, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Kiyoshi Chiba
- Shinagawa R&D Center, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Futoshi Nara
- Shin Nippon Biomedical Laboratories, Ltd., 8-1-28, Akashicho, Chuo-ku, Tokyo 104-0044, Japan
| | - Shinji Furuzono
- Shinagawa R&D Center, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| |
Collapse
|
3
|
Wei W, Xu Q, Wu L, Gong G, Tian Y, Huang H, Li Z. Drug development and potential targets for Cushing's syndrome. Eur J Med Chem 2024; 270:116333. [PMID: 38569434 DOI: 10.1016/j.ejmech.2024.116333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2023] [Revised: 03/11/2024] [Accepted: 03/13/2024] [Indexed: 04/05/2024]
Abstract
Cushing's syndrome (CS) is a complex disorder characterized by the excessive secretion of cortisol, with Cushing's disease (CD), particularly associated with pituitary tumors, exhibiting heightened morbidity and mortality. Although transsphenoidal pituitary surgery (TSS) stands as the primary treatment for CD, there is a crucial need to optimize patient prognosis. Current medical therapy serves as an adjunctive measure due to its unsatisfactory efficacy and unpredictable side effects. In this comprehensive review, we delve into recent advances in understanding the pathogenesis of CS and explore therapeutic options by conducting a critical analysis of potential drug targets and candidates. Additionally, we provide an overview of the design strategy employed in previously reported candidates, along with a summary of structure-activity relationship (SAR) analyses and their biological efficacy. This review aims to contribute valuable insights to the evolving landscape of CS research, shedding light on potential avenues for therapeutic development.
Collapse
Affiliation(s)
- Wei Wei
- Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, PR China
| | - Qianqian Xu
- Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, PR China
| | - Liuyi Wu
- Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, PR China
| | - Guangyue Gong
- Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, PR China
| | - Yucheng Tian
- Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, PR China
| | - Huidan Huang
- Center of Drug Screening & Evaluation, Wannan Medical College, Wuhu, Anhui, 241000, PR China.
| | - Zhiyu Li
- Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, PR China.
| |
Collapse
|
4
|
Maier P, Heinze B, Gabor S, Reese S, Hahner S, Schirbel A. Fluorinated aldosterone synthase (CYP11B2)-inhibitors for differential diagnosis between bilateral and unilateral conditions of primary aldosteronism. Bioorg Med Chem Lett 2023; 96:129501. [PMID: 37804995 DOI: 10.1016/j.bmcl.2023.129501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Revised: 09/25/2023] [Accepted: 10/04/2023] [Indexed: 10/09/2023]
Abstract
The enzyme aldosterone synthase (CYP11B2) is specifically expressed in aldosterone-producing tissue of the adrenal cortex and is overexpressed in aldosterone-producing adenomas (APA). It therefore represents an ideal target for molecular imaging, particularly for the differential diagnosis between bilateral hyperplasia and unilateral APA in primary aldosteronism. However, the presence of the cortisol-producing enzyme 11β-hydroxylase (CYP11B1) in the adrenal cortex remains very challenging owing to its high homology to CYP11B2. Within this study, we efficiently synthesized a variety of disubstituted fluorinated pyridines and pyrazines by Suzuki coupling reactions. These compounds were evaluated for their ability to inhibit CYP11B1 and CYP11B2 in transfected Y1 cells and in NCI-h295 cells. Several compounds were found to exhibit excellent affinity (IC50 < 10 nM) to CYP11B2 as well as strong selectivity (up to 125-fold) over CYP11B1. These findings support the further development of an analogous 18F-labelled PET tracer.
Collapse
Affiliation(s)
- Philipp Maier
- Department of Nuclear Medicine, University Hospital of Würzburg, University of Würzburg, 97080 Würzburg, Germany; University Clinic for Radiology and Nuclear Medicine, Otto von Guericke University (OvGU), 39120 Magdeburg, Germany; Division of Endocrinology & Diabetes, Department of Medicine I, University Hospital of Würzburg, University of Würzburg, 97080 Würzburg, Germany
| | - Britta Heinze
- Division of Endocrinology & Diabetes, Department of Medicine I, University Hospital of Würzburg, University of Würzburg, 97080 Würzburg, Germany
| | - Sabine Gabor
- Division of Endocrinology & Diabetes, Department of Medicine I, University Hospital of Würzburg, University of Würzburg, 97080 Würzburg, Germany
| | - Samario Reese
- Division of Endocrinology & Diabetes, Department of Medicine I, University Hospital of Würzburg, University of Würzburg, 97080 Würzburg, Germany
| | - Stefanie Hahner
- Division of Endocrinology & Diabetes, Department of Medicine I, University Hospital of Würzburg, University of Würzburg, 97080 Würzburg, Germany
| | - Andreas Schirbel
- Department of Nuclear Medicine, University Hospital of Würzburg, University of Würzburg, 97080 Würzburg, Germany.
| |
Collapse
|
5
|
Jäger MC, Kędzierski J, Gell V, Wey T, Kollár J, Winter DV, Schuster D, Smieško M, Odermatt A. Virtual screening and biological evaluation to identify pharmaceuticals potentially causing hypertension and hypokalemia by inhibiting steroid 11β-hydroxylase. Toxicol Appl Pharmacol 2023; 475:116638. [PMID: 37499767 DOI: 10.1016/j.taap.2023.116638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 07/21/2023] [Accepted: 07/24/2023] [Indexed: 07/29/2023]
Abstract
Several drugs were found after their market approval to unexpectedly inhibit adrenal 11β-hydroxylase (CYP11B1)-dependent cortisol synthesis. Known side-effects of CYP11B1 inhibition include hypertension and hypokalemia, due to a feedback activation of adrenal steroidogenesis, leading to supraphysiological concentrations of 11-deoxycortisol and 11-deoxycorticosterone that can activate the mineralocorticoid receptor. This results in potassium excretion and sodium and water retention, ultimately causing hypertension. With the risk known but usually not addressed in preclinical evaluation, this study aimed to identify drugs and drug candidates inhibiting CYP11B1. Two conceptually different virtual screening methods were combined, a pharmacophore based and an induced fit docking approach. Cell-free and cell-based CYP11B1 activity measurements revealed several inhibitors with IC50 values in the nanomolar range. Inhibitors include retinoic acid metabolism blocking agents (RAMBAs), azole antifungals, α2-adrenoceptor ligands, and a farnesyltransferase inhibitor. The active compounds share a nitrogen atom embedded in an aromatic ring system. Structure activity analysis identified the free electron pair of the nitrogen atom as a prerequisite for the drug-enzyme interaction, with its pKa value as an indicator of inhibitory potency. Another important parameter is drug lipophilicity, exemplified by etomidate. Changing its ethyl ester moiety to a more hydrophilic carboxylic acid group dramatically decreased the inhibitory potential, most likely due to less efficient cellular uptake. The presented work successfully combined different in silico and in vitro methods to identify several previously unknown CYP11B1 inhibitors. This workflow facilitates the identification of compounds that inhibit CYP11B1 and therefore pose a risk for inducing hypertension and hypokalemia.
Collapse
Affiliation(s)
- Marie-Christin Jäger
- Swiss Centre for Applied Human Toxicology (SCAHT), University of Basel, Missionsstrasse 64, 4055 Basel, Switzerland; Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.
| | - Jacek Kędzierski
- Swiss Centre for Applied Human Toxicology (SCAHT), University of Basel, Missionsstrasse 64, 4055 Basel, Switzerland; Division of Computational Pharmacy, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland.
| | - Victoria Gell
- Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland; Division of Computational Pharmacy, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland.
| | - Tim Wey
- Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.
| | - Jakub Kollár
- Institute of Pharmacy, Department of Pharmaceutical and Medicinal Chemistry, Paracelsus Medical University, Strubergasse 21, 5020 Salzburg, Austria.
| | - Denise V Winter
- Swiss Centre for Applied Human Toxicology (SCAHT), University of Basel, Missionsstrasse 64, 4055 Basel, Switzerland; Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.
| | - Daniela Schuster
- Institute of Pharmacy, Department of Pharmaceutical and Medicinal Chemistry, Paracelsus Medical University, Strubergasse 21, 5020 Salzburg, Austria.
| | - Martin Smieško
- Swiss Centre for Applied Human Toxicology (SCAHT), University of Basel, Missionsstrasse 64, 4055 Basel, Switzerland; Division of Computational Pharmacy, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland.
| | - Alex Odermatt
- Swiss Centre for Applied Human Toxicology (SCAHT), University of Basel, Missionsstrasse 64, 4055 Basel, Switzerland; Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland.
| |
Collapse
|
6
|
In silico selectivity modeling of pyridine and pyrimidine based CYP11B1 and CYP11B2 inhibitors: A case study. J Mol Graph Model 2022; 116:108238. [PMID: 35691091 DOI: 10.1016/j.jmgm.2022.108238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 05/26/2022] [Accepted: 05/26/2022] [Indexed: 12/14/2022]
Abstract
DESIGN of selective drug candidates for highly structural similar targets is a challenging task for researchers. The main objective of this study was to explore the selectivity modeling of pyridine and pyrimidine scaffold towards the highly homologous targets CYP11B1 and CYP11B2 enzymes by in silico (Molecular docking and QSAR) approaches. In this regard, a big dataset (n = 228) of CYP11B1 and CYP11B2 inhibitors were gathered and classified based on heterocyclic ring and the exhaustive analysis was carried out for pyridine and pyrimidinescaffolds. The LibDock algorithm was used to explore the binding pattern, screening, and identify the structural feature responsible for the selectivity of the ligands towards the studied targets. Finally, QSAR analysis was done to explore the correlation between various binding parameters and structural features responsible for the inhibitory activity and selectivity of the ligands in a quantitative way. The docking and QSAR analysis clearly revealed and distinguished the importance of structural features, functional groups attached for CYP11B2 and CYP11B1 selectivity for pyridine and pyrimidine analogs. Additionally, the docking analysis highlighted the differentiating amino acids residues for selectivity for ligands for each of the enzymes. The results obtained from this research work will be helpful in designing the selective CYP11B1/CYP11B2 inhibitors.
Collapse
|
7
|
Hamada S, Yano K, Kobayashi Y, Kawabata T, Furuta T. Oxidaition of cyclic benzylic ethers by an electronically tuned nitroxyl radical. Tetrahedron Lett 2021. [DOI: 10.1016/j.tetlet.2021.153404] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Wu J, Ding X, Tan X. A patent review of aldosterone synthase inhibitors (2014-present). Expert Opin Ther Pat 2021; 32:13-28. [PMID: 34365871 DOI: 10.1080/13543776.2021.1965991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
INTRODUCTION Aldosterone synthase (AS) is a key enzyme involved in the final three rate-limiting steps of the biosynthesis pathway of aldosterone, and its inhibition has been considered as an effective strategy to treat hypertension, heart failure, and related cardio-metabolic diseases. AREA COVERED This review provides an update on the discovery and development of aldosterone synthase inhibitors by means of patents published between January 2014 and March 2021. The molecules are classified by pharmaceutical company with progress that has been made in clinical trials being highlighted. EXPERT OPINION Mineralocorticoid receptor antagonists (MRAs) and aldosterone synthase inhibitors (ASI) represent two of the main approaches for the blockade of aldosterone. Clinical success, as well as foreseen side effects of steroidal MRAs, prompted the discovery and development of ASI. Since the observation of decreased cortisol levels in clinical trials for LCI699, subsequent efforts have been largely focused on improving its selectivity over hCYP11B1. Candidates with improved potency and selectivity are under investigation across a wide range of indications. Whether ASI will provide an additional therapeutic advantage over current safe and selective non-steroidal MRAs is highly anticipated.
Collapse
Affiliation(s)
- Jun Wu
- Department of Medicinal Chemistry, Roche Innovation Center Shanghai, Roche Pharma Research and Early Development, Shanghai, China
| | - Xiao Ding
- Department of Medicinal Chemistry, Roche Innovation Center Shanghai, Roche Pharma Research and Early Development, Shanghai, China
| | - Xuefei Tan
- Department of Medicinal Chemistry, Roche Innovation Center Shanghai, Roche Pharma Research and Early Development, Shanghai, China
| |
Collapse
|
9
|
Aldosterone synthase inhibitors for cardiovascular diseases: A comprehensive review of preclinical, clinical and in silico data. Pharmacol Res 2020; 163:105332. [PMID: 33271294 DOI: 10.1016/j.phrs.2020.105332] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/27/2020] [Revised: 10/27/2020] [Accepted: 11/23/2020] [Indexed: 01/23/2023]
Abstract
Aldosterone, the main mineralocorticoid hormone, plays a fundamental role in maintaining blood pressure (BP)and volume under hypovolemic conditions. However, in numerous diseases, where it is produced in excess, it plays a detrimental role and contributes to cardiovascular events and ultimately to death in a multitude of patients. The seminal observation that the fungicide-derivative fadrozole blunted steroidogenesis has led to develop several agents to inhibit aldosterone synthase (AS, CYP11B2), the mitochondrial NADH-dependent enzyme that is necessary for aldosterone biosynthesis. Aldosterone synthase inhibitors (ASI) have, thereafter, been conceived and investigated in phase I and phase II studies. We herein reviewed the ASIs available so far considering their chemical structure, the related aldosterone synthase binding and pharmacodynamic properties. We also examined the promising results obtained with ASIs that have already been tested in phase II human studies.
Collapse
|
10
|
Braun LT, Reincke M. What is the role of medical therapy in adrenal-dependent Cushing's syndrome? Best Pract Res Clin Endocrinol Metab 2020; 34:101376. [PMID: 32063487 DOI: 10.1016/j.beem.2020.101376] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Medical therapy to control hypercortisolism in adrenal Cushing's syndrome is currently not the first-line therapy. However, in many clinical scenarios like pre-surgical treatment, in patients who are not suitable candidates for surgery or in patients with bilateral hyperplasia, medical therapy can be important representing the only viable treatment option. Adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers have been used for many years: metyrapone, ketoconazole and mifepristone are in current use and effective. Mitotane can be used as well but is considered second-line therapy because of its high toxicity. Etomidate has a special position as emergency medication in severe hypercortisolism. New drugs are tested in prospective trials (levoketoconazole, osilidrostat and relacorilant) and might become effective alternatives to common drugs. Oher drugs - adrenal steroidogenesis inhibitors as well as glucocorticoid receptor antagonists - are currently tested in vitro.
Collapse
Affiliation(s)
- Leah T Braun
- Medizinische Klinik und Poliklinik IV, Department for Endocrinology, Ludwig-Maximilians-University, Munich, Germany.
| | - Martin Reincke
- Medizinische Klinik und Poliklinik IV, Department for Endocrinology, Ludwig-Maximilians-University, Munich, Germany.
| |
Collapse
|
11
|
Rendic SP, Peter Guengerich F. Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits. Drug Metab Rev 2019; 50:256-342. [PMID: 30717606 DOI: 10.1080/03602532.2018.1483401] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Cytochrome P450 (P450, CYP) enzymes have long been of interest due to their roles in the metabolism of drugs, pesticides, pro-carcinogens, and other xenobiotic chemicals. They have also been of interest due to their very critical roles in the biosynthesis and metabolism of steroids, vitamins, and certain eicosanoids. This review covers the 22 (of the total of 57) human P450s in Families 5-51 and their substrate selectivity. Furthermore, included is information and references regarding inducibility, inhibition, and (in some cases) stimulation by chemicals. We update and discuss important aspects of each of these 22 P450s and questions that remain open.
Collapse
Affiliation(s)
| | - F Peter Guengerich
- b Department of Biochemistry , Vanderbilt University School of Medicine , Nashville , TN , USA
| |
Collapse
|
12
|
Usanov SA, Kliuchenovich AV, Strushkevich NV. Drug design strategies for Cushing's syndrome. Expert Opin Drug Discov 2018; 14:143-151. [PMID: 30572739 DOI: 10.1080/17460441.2019.1559146] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
INTRODUCTION Cushing's syndrome (CS) is a metabolic disorder caused by chronic hypercortisolism. CS is associated with cardiovascular, metabolic, skeletal and psychological dysfunctions and can be fatal if left untreated. The first-line treatment for all forms of CS is a surgery. However, medical therapy has to be chosen if surgical resection is not an option or is deemed ineffective. Currently available therapeutics are either not selective and have side effects or are only available as an injection (pasireotide). Areas covered: The authors discuss the recent drug developments for the medical treatment of CS through two validated molecular targets. Specifically, the authors look at selective inhibitors of CYP11B1 that reduce cortisol production by inhibiting steroid 11beta-hydroxylase and glucocorticoid receptor (GR) antagonists that interrupt cortisol-mediating transcriptional regulation of related genes. Expert opinion: Patients with CS have limited treatment options; indeed, there is an unmet need for new compounds that target CYP11B1 selectively versus several steroidogenic enzymes and/or GR-signaling pathways. The complexity of steroid biosynthesis and signaling requires the application of structure-based drug discovery techniques that use molecular targets and highly similar off-targets. Significant differences in steroidogenesis between humans and other species necessitates caution over the choice of in vivo model for the preclinical evaluation of future potential compounds.
Collapse
Affiliation(s)
- S A Usanov
- a Institute of Bioorganic Chemistry of the National Academy of Science of Belarus , Minsk , Republic of Belarus
| | - A V Kliuchenovich
- b Target Medicals LLC , Skolkovo Innovation Center (Technopark) , Moscow , Russian Federation
| | - N V Strushkevich
- a Institute of Bioorganic Chemistry of the National Academy of Science of Belarus , Minsk , Republic of Belarus
| |
Collapse
|
13
|
Abstract
The mineralocorticoid aldosterone is an important regulator of blood pressure and electrolyte balance. However, excess aldosterone can be deleterious as a driver of inflammation, vascular remodeling and tissue fibrosis associated with cardiometabolic diseases. Mineralocorticoid receptor antagonists (MRA) and renin-angiotensin-aldosterone system (RAAS) antagonists are current clinical therapies used to antagonize deleterious effects of aldosterone in patients. MRAs compete with aldosterone for binding at its cognate receptor thereby limiting its effect while RAS antagonists reduce aldosterone levels indirectly by blocking the stimulatory effect of angiotensin. Both MRAs and RAS antagonists can result in incomplete inhibition of the harmful effects of excess aldosterone. Aldosterone synthase (AS) inhibitors (ASI) attenuate the production of aldosterone directly and have been proposed as an alternative to MRAs and RAS blockers. Cortisol synthase (CS) is an enzyme closely related to AS and responsible for generating the important glucocorticoid cortisol, required for maintaining critical metabolic and immune responses. The importance of selectivity against CS is shown by early examples of ASIs that were only modestly selective and as such, attenuated cortisol responses when evaluated in patients. Recently, next-generation, highly selective ASIs have been described and are presently being evaluated in the clinic as an alternative to angiotensin and MR antagonists for cardiometabolic disease. Herein we provide a brief review of the challenges associated with discovery of selective ASIs and the transition from the early compounds that paved the way toward the next-generation of highly selective ASIs currently under development.
Collapse
Affiliation(s)
- Steven M Weldon
- Cardiometabolic Disease Research, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.
| | - Nicholas F Brown
- Cardiometabolic Disease Research, Boehringer-Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States
| |
Collapse
|
14
|
Nishiyori R, Tsuchihashi A, Mochizuki A, Kaneko K, Yamanaka M, Shirakawa S. Design of Chiral Bifunctional Dialkyl Sulfide Catalysts for Regio-, Diastereo-, and Enantioselective Bromolactonization. Chemistry 2018; 24:16747-16752. [PMID: 30203864 DOI: 10.1002/chem.201803703] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2018] [Revised: 09/10/2018] [Indexed: 11/09/2022]
Abstract
Although a wide variety of chiral organocatalysts have been developed for asymmetric transformations, effective chiral dialkyl sulfide organocatalysts remain relatively rare and under-developed, despite the potential utility of dialkyl sulfide catalysts. Herein, we report the development of chiral bifunctional dialkyl sulfide catalysts possessing a urea moiety for regio-, diastereo-, and enantioselective bromolactonization. The importance of the bifunctional design of chiral sulfide catalysts was clearly demonstrated in the present work. The roles of both the sulfide and urea moieties of the catalyst were clarified based on the results of experimental and theoretical investigation.
Collapse
Affiliation(s)
- Ryuichi Nishiyori
- Department of Environmental Science, Graduate School of Fisheries and Environmental Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki, 852-8521, Japan
| | - Ayano Tsuchihashi
- Department of Environmental Science, Graduate School of Fisheries and Environmental Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki, 852-8521, Japan
| | - Ayaka Mochizuki
- Department of Chemistry and Research Center for Smart Molecules, Faculty of Science, Rikkyo University, 3-34-1, Nishi-Ikebukuro, Toshima-ku, Tokyo, 171-8501, Japan
| | - Kazuma Kaneko
- Department of Chemistry and Research Center for Smart Molecules, Faculty of Science, Rikkyo University, 3-34-1, Nishi-Ikebukuro, Toshima-ku, Tokyo, 171-8501, Japan
| | - Masahiro Yamanaka
- Department of Chemistry and Research Center for Smart Molecules, Faculty of Science, Rikkyo University, 3-34-1, Nishi-Ikebukuro, Toshima-ku, Tokyo, 171-8501, Japan
| | - Seiji Shirakawa
- Department of Environmental Science, Graduate School of Fisheries and Environmental Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki, 852-8521, Japan
| |
Collapse
|
15
|
Sakakibara R, Sasaki W, Onda Y, Yamaguchi M, Ushirogochi H, Hiraga Y, Sato K, Nishio M, Egi Y, Takedomi K, Shimizu H, Ohbora T, Akahoshi F. Discovery of Novel Pyrazole-Based Selective Aldosterone Synthase (CYP11B2) Inhibitors: A New Template to Coordinate the Heme-Iron Motif of CYP11B2. J Med Chem 2018; 61:5594-5608. [DOI: 10.1021/acs.jmedchem.8b00328] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Ryo Sakakibara
- Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda, Saitama 335-8505, Japan
| | - Wataru Sasaki
- Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda, Saitama 335-8505, Japan
| | - Yuichi Onda
- Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda, Saitama 335-8505, Japan
| | - Minami Yamaguchi
- Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda, Saitama 335-8505, Japan
| | - Hideki Ushirogochi
- Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda, Saitama 335-8505, Japan
| | - Yuki Hiraga
- Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda, Saitama 335-8505, Japan
| | - Kanako Sato
- Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda, Saitama 335-8505, Japan
| | - Masashi Nishio
- Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda, Saitama 335-8505, Japan
| | - Yasuhiro Egi
- Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda, Saitama 335-8505, Japan
| | - Kei Takedomi
- Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda, Saitama 335-8505, Japan
| | - Hidetoshi Shimizu
- Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda, Saitama 335-8505, Japan
| | - Tomoko Ohbora
- Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda, Saitama 335-8505, Japan
| | - Fumihiko Akahoshi
- Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, 2-2-50, Kawagishi, Toda, Saitama 335-8505, Japan
| |
Collapse
|
16
|
Burg F, Gicquel M, Breitenlechner S, Pöthig A, Bach T. Katalytische, positions- und enantioselektive C-H-Oxygenierung durch einen chiralen Mangan-Porphyrin-Komplex mit einer entfernten Bindungsstelle. Angew Chem Int Ed Engl 2018. [DOI: 10.1002/ange.201712340] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Finn Burg
- Fakultät für Chemie und Zentralinstitut für Katalyseforschung; Technische Universität München; Lichtenbergstraße 4 85747 Garching Deutschland
| | - Maxime Gicquel
- Fakultät für Chemie und Zentralinstitut für Katalyseforschung; Technische Universität München; Lichtenbergstraße 4 85747 Garching Deutschland
| | - Stefan Breitenlechner
- Fakultät für Chemie und Zentralinstitut für Katalyseforschung; Technische Universität München; Lichtenbergstraße 4 85747 Garching Deutschland
| | - Alexander Pöthig
- Fakultät für Chemie und Zentralinstitut für Katalyseforschung; Technische Universität München; Lichtenbergstraße 4 85747 Garching Deutschland
| | - Thorsten Bach
- Fakultät für Chemie und Zentralinstitut für Katalyseforschung; Technische Universität München; Lichtenbergstraße 4 85747 Garching Deutschland
| |
Collapse
|
17
|
Burg F, Gicquel M, Breitenlechner S, Pöthig A, Bach T. Site- and Enantioselective C−H Oxygenation Catalyzed by a Chiral Manganese Porphyrin Complex with a Remote Binding Site. Angew Chem Int Ed Engl 2018; 57:2953-2957. [DOI: 10.1002/anie.201712340] [Citation(s) in RCA: 75] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2017] [Indexed: 11/09/2022]
Affiliation(s)
- Finn Burg
- Department Chemie and Catalysis Research Center (CRC); Technische Universität München; Lichtenbergstraße 4 85747 Garching Germany
| | - Maxime Gicquel
- Department Chemie and Catalysis Research Center (CRC); Technische Universität München; Lichtenbergstraße 4 85747 Garching Germany
| | - Stefan Breitenlechner
- Department Chemie and Catalysis Research Center (CRC); Technische Universität München; Lichtenbergstraße 4 85747 Garching Germany
| | - Alexander Pöthig
- Department Chemie and Catalysis Research Center (CRC); Technische Universität München; Lichtenbergstraße 4 85747 Garching Germany
| | - Thorsten Bach
- Department Chemie and Catalysis Research Center (CRC); Technische Universität München; Lichtenbergstraße 4 85747 Garching Germany
| |
Collapse
|
18
|
Talele TT. Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry. J Med Chem 2017; 61:2166-2210. [DOI: 10.1021/acs.jmedchem.7b00315] [Citation(s) in RCA: 67] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- Tanaji T. Talele
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, New York 11439, United States
| |
Collapse
|
19
|
Hoyt SB, Taylor J, London C, Ali A, Ujjainwalla F, Tata J, Struthers M, Cully D, Wisniewski T, Ren N, Bopp C, Sok A, Verras A, McMasters D, Chen Q, Tung E, Tang W, Salituro G, Clemas J, Zhou G, MacNeil D, Duffy R, Xiong Y. Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension. Bioorg Med Chem Lett 2017; 27:2384-2388. [DOI: 10.1016/j.bmcl.2017.04.021] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Revised: 03/10/2017] [Accepted: 04/06/2017] [Indexed: 12/11/2022]
|
20
|
Meguro M, Miyauchi S, Kanao Y, Naito S, Suzuki K, Inoue S, Yamada K, Homma T, Chiba K, Nara F, Furuzono S. 4-Anilino-pyrimidine, novel aldosterone synthase (CYP11B2) inhibitors bearing pyrimidine structures. Bioorg Med Chem Lett 2017; 27:1902-1906. [DOI: 10.1016/j.bmcl.2017.03.034] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2017] [Revised: 03/14/2017] [Accepted: 03/16/2017] [Indexed: 01/20/2023]
|
21
|
Petrilli WL, Hoyt SB, London C, McMasters D, Verras A, Struthers M, Cully D, Wisniewski T, Ren N, Bopp C, Sok A, Chen Q, Li Y, Tung E, Tang W, Salituro G, Knemeyer I, Karanam B, Clemas J, Zhou G, Gibson J, Shipley CA, MacNeil DJ, Duffy R, Tata JR, Ujjainwalla F, Ali A, Xiong Y. Discovery of Spirocyclic Aldosterone Synthase Inhibitors as Potential Treatments for Resistant Hypertension. ACS Med Chem Lett 2017; 8:128-132. [PMID: 28105288 PMCID: PMC5238464 DOI: 10.1021/acsmedchemlett.6b00455] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2016] [Accepted: 11/22/2016] [Indexed: 01/26/2023] Open
Abstract
Herein we report the discovery and hit-to-lead optimization of a series of spirocyclic piperidine aldosterone synthase (CYP11B2) inhibitors. Compounds from this series display potent CYP11B2 inhibition, good selectivity versus related CYP enzymes, and lead-like physical and pharmacokinetic properties.
Collapse
Affiliation(s)
- Whitney L. Petrilli
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Scott B. Hoyt
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Clare London
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Daniel McMasters
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Andreas Verras
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Mary Struthers
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Doris Cully
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Thomas Wisniewski
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Ning Ren
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Charlene Bopp
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Andrea Sok
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Qing Chen
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Ying Li
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Elaine Tung
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Wei Tang
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Gino Salituro
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Ian Knemeyer
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Bindhu Karanam
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Joseph Clemas
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Gaochao Zhou
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Jack Gibson
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Carrie Ann Shipley
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Douglas J. MacNeil
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Ruth Duffy
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - James R. Tata
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Feroze Ujjainwalla
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Amjad Ali
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| | - Yusheng Xiong
- Departments
of Discovery Chemistry, Chemistry Modeling & Informatics, Hypertension, Drug Metabolism
& Pharmacokinetics, and In Vitro Pharmacology, Merck Research Laboratories, Rahway, New Jersey 07065, United States
| |
Collapse
|
22
|
Peng P, Wang J, Jiang H, Liu H. Rhodium(III)-Catalyzed Site-Selective C-H Alkylation and Arylation of Pyridones Using Organoboron Reagents. Org Lett 2016; 18:5376-5379. [PMID: 27736078 DOI: 10.1021/acs.orglett.6b02755] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
In this study we developed a method for the pyridine-directed, rhodium-catalyzed, site-selective C-H alkylation and arylation of pyridones using commercially available trifluoroborate reagents. This simple and versatile transformation proceeded smoothly under relatively mild conditions with perfect site selectivity. The coupling groups in the boron reagents can be extended to primary alkyl, benzyl, and cycloalkyl. Moreover, direct C-H arylation products could also be obtained under similar conditions.
Collapse
Affiliation(s)
- Panfeng Peng
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China.,School of Pharmaceutical Engineering, Shenyang Pharmaceutical University , 103 Wen Hua Road, Liaoning, Shenyang 110016, China
| | - Jiang Wang
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China
| | - Hualiang Jiang
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China.,School of Pharmaceutical Engineering, Shenyang Pharmaceutical University , 103 Wen Hua Road, Liaoning, Shenyang 110016, China
| | - Hong Liu
- CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , 555 Zu Chong Zhi Road, Shanghai 201203, P. R. China
| |
Collapse
|
23
|
Mieriņa I, Jure M, Stikute A. Synthetic approaches to 4-(het)aryl-3,4-dihydroquinolin-2(1H)-ones. Chem Heterocycl Compd (N Y) 2016. [DOI: 10.1007/s10593-016-1920-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
24
|
Gobbi S, Hu Q, Zimmer C, Belluti F, Rampa A, Hartmann RW, Bisi A. Targeting Steroidogenic Cytochromes P450 (CYPs) with 6-Substituted 1-Imidazolylmethylxanthones. ChemMedChem 2016; 11:1770-7. [DOI: 10.1002/cmdc.201600078] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Revised: 03/11/2016] [Indexed: 12/26/2022]
Affiliation(s)
- Silvia Gobbi
- Department of Pharmacy and Biotechnology; University of Bologna; Via Belmeloro 6 40126 Bologna Italy
| | - Qingzhong Hu
- Pharmaceutical and Medicinal Chemistry; Saarland University & Helmholtz Institute for Pharmaceutical Research Saarland (HIPS); Universitätscampus E8 1 66123 Saarbrücken Germany
- Department of Chemistry; University of Cambridge; Lensfield Road Cambridge CB2 1EW UK
| | - Christina Zimmer
- Pharmaceutical and Medicinal Chemistry; Saarland University & Helmholtz Institute for Pharmaceutical Research Saarland (HIPS); Universitätscampus E8 1 66123 Saarbrücken Germany
| | - Federica Belluti
- Department of Pharmacy and Biotechnology; University of Bologna; Via Belmeloro 6 40126 Bologna Italy
| | - Angela Rampa
- Department of Pharmacy and Biotechnology; University of Bologna; Via Belmeloro 6 40126 Bologna Italy
| | - Rolf W. Hartmann
- Pharmaceutical and Medicinal Chemistry; Saarland University & Helmholtz Institute for Pharmaceutical Research Saarland (HIPS); Universitätscampus E8 1 66123 Saarbrücken Germany
| | - Alessandra Bisi
- Department of Pharmacy and Biotechnology; University of Bologna; Via Belmeloro 6 40126 Bologna Italy
| |
Collapse
|
25
|
Affiliation(s)
- Rita Bernhardt
- Lehrstuhl für Biochemie, Universität des Saarlandes, Saarbrücken, Germany
| |
Collapse
|
26
|
Martin RE, Lehmann J, Alzieu T, Lenz M, Carnero Corrales MA, Aebi JD, Märki HP, Kuhn B, Amrein K, Mayweg AV, Britton R. Synthesis of annulated pyridines as inhibitors of aldosterone synthase (CYP11B2). Org Biomol Chem 2016; 14:5922-7. [DOI: 10.1039/c6ob00848h] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
A series of potent and selective aldosterone synthase (CYP11B2) inhibitors were prepared in one step through an intermolecular Kondrat'eva reaction.
Collapse
|
27
|
Papillon JPN, Lou C, Singh AK, Adams CM, Ksander GM, Beil ME, Chen W, Leung-Chu J, Fu F, Gan L, Hu CW, Jeng AY, LaSala D, Liang G, Rigel DF, Russell KS, Vest JA, Watson C. Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects. J Med Chem 2015; 58:9382-94. [PMID: 26540564 DOI: 10.1021/acs.jmedchem.5b01545] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Human clinical studies conducted with LCI699 established aldosterone synthase (CYP11B2) inhibition as a promising novel mechanism to lower arterial blood pressure. However, LCI699's low CYP11B1/CYP11B2 selectivity resulted in blunting of adrenocorticotropic hormone-stimulated cortisol secretion. This property of LCI699 prompted its development in Cushing's disease, but limited more extensive clinical studies in hypertensive populations, and provided an impetus for the search for cortisol-sparing CYP11B2 inhibitors. This paper summarizes the discovery, pharmacokinetics, and pharmacodynamic data in preclinical species and human subjects of the selective CYP11B2 inhibitor 8.
Collapse
Affiliation(s)
| | | | | | | | | | - Michael E Beil
- Cardiovascular and Metabolism, Novartis Institutes for BioMedical Research , One Health Plaza, East Hanover, New Jersey 07936, United States
| | - Wei Chen
- Cardiovascular and Metabolism, Novartis Institutes for BioMedical Research , One Health Plaza, East Hanover, New Jersey 07936, United States
| | - Jennifer Leung-Chu
- Cardiovascular and Metabolism, Novartis Institutes for BioMedical Research , One Health Plaza, East Hanover, New Jersey 07936, United States
| | - Fumin Fu
- Cardiovascular and Metabolism, Novartis Institutes for BioMedical Research , One Health Plaza, East Hanover, New Jersey 07936, United States
| | | | - Chii-Whei Hu
- Cardiovascular and Metabolism, Novartis Institutes for BioMedical Research , One Health Plaza, East Hanover, New Jersey 07936, United States
| | - Arco Y Jeng
- Cardiovascular and Metabolism, Novartis Institutes for BioMedical Research , One Health Plaza, East Hanover, New Jersey 07936, United States
| | - Daniel LaSala
- Cardiovascular and Metabolism, Novartis Institutes for BioMedical Research , One Health Plaza, East Hanover, New Jersey 07936, United States
| | | | - Dean F Rigel
- Cardiovascular and Metabolism, Novartis Institutes for BioMedical Research , One Health Plaza, East Hanover, New Jersey 07936, United States
| | | | | | | |
Collapse
|
28
|
Cerny MA, Csengery A, Schmenk J, Frederick K. Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human. J Steroid Biochem Mol Biol 2015; 154:197-205. [PMID: 26303746 DOI: 10.1016/j.jsbmb.2015.08.004] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Revised: 08/03/2015] [Accepted: 08/05/2015] [Indexed: 01/04/2023]
Abstract
Elevated levels of aldosterone are associated with arterial hypertension, congestive heart failure, chronic kidney disease, and obesity. Aldosterone is produced predominantly in the zona glomerulosa of the cortex of the adrenal gland by the enzyme aldosterone synthase (CYP11B2). Treatment of the above indications by decreasing production of aldosterone is thought to be of therapeutic benefit by lessening the deleterious effects of aldosterone mediated through both the mineralocorticoid receptor and also through so called non-genomic pathways. However, inhibition of the highly similar enzyme, CYP11B1, which is responsible for the production of cortisol, must be avoided in the development of clinically useful aldosterone synthase inhibitors due to the resulting impairment of the cortisol-induced stress response. In efforts to assess the interactions of compounds with the CYP11B enzymes, a variety of cell-based inhibitor screening assays for both CYP11B1 and CYP11B2 have been reported. Herein we report details of assays employing both cynomolgus monkey adrenal homogenate (CAH) and human adrenal homogenate (HAH) as sources of CYP11B1 and CYP11B2 enzymes. Utilizing both CAH and HAH, we have characterized the kinetics of the CYP11B1-mediated conversion of 11-deoxycortisol to cortisol and the CYP11B2-mediated oxidation of corticosterone to aldosterone. Inhibition assays for both CYP11B1 and CYP11B2 were subsequently developed. Based on a comparison of human and monkey amino acid sequences, kinetics data, and inhibition values derived from the HAH and CAH assays, evidence is provided in support of using cynomolgus monkey tissue-derived cell homogenates as suitable surrogates for the human enzymes.
Collapse
Affiliation(s)
- Matthew A Cerny
- Boehringer Ingelheim Pharmaceuticals, Inc., Department of Medicinal Chemistry, Drug Discovery Support (DMPK), USA.
| | - Alexander Csengery
- Boehringer Ingelheim Pharmaceuticals, Inc., Department of Medicinal Chemistry, Drug Discovery Support (DMPK), USA
| | - Jennifer Schmenk
- Boehringer Ingelheim Pharmaceuticals, Inc., Department of Medicinal Chemistry, Drug Discovery Support (DMPK), USA
| | - Kosea Frederick
- Boehringer Ingelheim Pharmaceuticals, Inc., Department of Medicinal Chemistry, Drug Discovery Support (DMPK), USA
| |
Collapse
|